<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05095727</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-3745-P102</org_study_id>
    <nct_id>NCT05095727</nct_id>
  </id_info>
  <brief_title>A Study of mRNA-3745 in Participants With Glycogen Storage Disease Type 1a (GSD1a)</brief_title>
  <official_title>An Open-Label Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-3745 in Participants With Glycogen Storage Disease Type 1a (GSD1a)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this trial is to evaluate the safety and tolerability of mRNA-3745 via&#xD;
      intravenous (IV) administration in participants with GSD1a.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose escalation study in adult participants with GSD1a to determine the safety and&#xD;
      tolerability of mRNA-3745 and characterize the pharmacokinetic (PK) and pharmacodynamic (PD)&#xD;
      response following IV administration of a single dose of mRNA-3745.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 17, 2022</start_date>
  <completion_date type="Anticipated">January 19, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 19, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With No Hypoglycemic Events for up to 8 Hours During Fasting Challenges</measure>
    <time_frame>Baseline through Week 52</time_frame>
    <description>Hypoglycemia is defined as blood glucose &lt;60 milligrams (mg)/deciliter (dL) (3.3 millimoles [mmol]/liter [L]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Area Under the Effect Curve (AUEC) of Blood Glucose and Lactate During Fasting Challenges</measure>
    <time_frame>Baseline through Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Time to Hypoglycemia During Fasting Challenges</measure>
    <time_frame>Baseline through Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Maximum Effect (Emax) During Fasting Challenges</measure>
    <time_frame>Baseline through Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of mRNA and LNP</measure>
    <time_frame>Pre-infusion, at mid-infusion, and at the end of infusion (EOI) on Day 1 up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax of mRNA and LNP</measure>
    <time_frame>Pre-infusion, at mid-infusion, and at EOI on Day 1 up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve From Time 0 to the Time of the Last Measurable Serum Concentration (AUC0-t) of mRNA and LNP</measure>
    <time_frame>Pre-infusion, at mid-infusion, and at EOI on Day 1 up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2) of mRNA and LNP</measure>
    <time_frame>Pre-infusion, at mid-infusion, and at EOI on Day 1 up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of mRNA and LNP</measure>
    <time_frame>Pre-infusion, at mid-infusion, and at EOI on Day 1 up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State of mRNA and LNP</measure>
    <time_frame>Pre-infusion, at mid-infusion, and at EOI on Day 1 up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Metabolic Biomarkers</measure>
    <time_frame>Baseline through Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Glycogen Storage Disease</condition>
  <arm_group>
    <arm_group_label>mRNA-3745</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IV dose of mRNA-3745 on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mRNA-3745</intervention_name>
    <description>Sterile frozen liquid dispersion for injection</description>
    <arm_group_label>mRNA-3745</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented GSD1a with confirmation by genetic testing&#xD;
&#xD;
          -  Documented history of â‰¥1 hypoglycemic event with blood glucose &lt;60&#xD;
             milligrams/deciliter (mg/dL) (&lt;3.3 millimoles/liter [mmol/L]) and symptoms of&#xD;
             hypoglycemia in the absence of acute illness, with at least one such event in the 4&#xD;
             weeks before signing the Informed Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Liver transplant, including hepatocyte cell therapy/transplant&#xD;
&#xD;
          -  Received gene therapy for GSD1a&#xD;
&#xD;
          -  Presence of liver adenoma &gt;5 centimeters (cm) in size&#xD;
&#xD;
          -  Presence of liver adenoma with growth of &gt;2 cm or &gt;5 newly diagnosed liver adenoma, in&#xD;
             the previous 2 years.&#xD;
&#xD;
        Note: Additional inclusion/exclusion criteria may apply, per protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moderna Clinical Trials</last_name>
    <phone>877-913-3286</phone>
    <email>clinicaltrials@modernatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cao J, Choi M, Guadagnin E, Soty M, Silva M, Verzieux V, Weisser E, Markel A, Zhuo J, Liang S, Yin L, Frassetto A, Graham AR, Burke K, Ketova T, Mihai C, Zalinger Z, Levy B, Besin G, Wolfrom M, Tran B, Tunkey C, Owen E, Sarkis J, Dousis A, Presnyak V, Pepin C, Zheng W, Ci L, Hard M, Miracco E, Rice L, Nguyen V, Zimmer M, Rajarajacholan U, Finn PF, Mithieux G, Rajas F, Martini PGV, Giangrande PH. mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease. Nat Commun. 2021 May 25;12(1):3090. doi: 10.1038/s41467-021-23318-2.</citation>
    <PMID>34035281</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glycogen storage disease type 1a</keyword>
  <keyword>GSD1a</keyword>
  <keyword>Von Gierke disease</keyword>
  <keyword>Glucose metabolism disorder</keyword>
  <keyword>Genetic disorder</keyword>
  <keyword>Autosomal recessive disorder</keyword>
  <keyword>messenger RNA</keyword>
  <keyword>mRNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

